NTRK1 and cancer: We investigated the mechanism(s) responsible for this ERK reactivation and hypothesized that targeting tyrosine‐protein kinase receptor UFO (AXL), another receptor tyrosine kinase that has been implicated in cancer resistance, may overcome the adaptive ERK reactivation.